Clinical genomics software market seen reaching $5.7 billion by 2030

The clinical genomics software market is projected to grow from $2.85 billion in 2025 to $3.28 billion in 2026, then climb to $5.7 billion by 2030 as precision medicine, genomic diagnostics and cloud-based platforms gain traction. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Clinical genomics software is becoming a core layer in precision medicine, helping clinicians interpret genetic data for diagnosis, treatment selection and research. - Faster adoption could improve how healthcare systems handle rare diseases, cancer testing and other conditions that rely on genomic insight. - The market’s expected growth signals continued investment in tools that connect sequencing data, clinical workflows and electronic health records.

What happened: - The Business Research Company published its Clinical Genomics Software Global Market Report 2026 covering market size, trends and forecasts through 2035. - The report estimates the market at $2.85 billion in 2025 and $3.28 billion in 2026, implying 15.2% annual growth. - The report projects the market will reach $5.7 billion by 2030 at a 14.8% CAGR. - North America was the largest regional market in 2025. - Asia-Pacific is forecast to post the fastest growth over the next several years. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample is available here. - The full report is available here.

The details: - Clinical genomics software includes digital platforms and analytical applications for handling, interpreting and visualizing genomic and molecular data. - The software supports sequencing workflows, variant identification and analysis, data integration and reporting. - Historic market growth has been driven by lower genome sequencing costs, more research into rare diseases, early use of bioinformatics tools, rising cancer incidence and improvements in laboratory information management systems. - Future growth is expected to come from broader precision medicine adoption, deeper use of genomics in routine diagnostics, personalized drug development, cloud-based genomic data platforms and larger genomic screening programs. - Key trends include demand for genomic data interoperability, stronger regulatory compliance, tighter EHR integration, patient-centric precision diagnostics workflows and secure genomic data storage with privacy-focused analytics.

Between the lines: - The forecast points to a market moving from research support toward routine clinical infrastructure. - The emphasis on interoperability and EHR integration suggests buyers want genomics tools that fit existing hospital systems, not standalone software. - The February 2024 update from the Personalized Medicine Coalition showed the FDA approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022. - That jump underscores how regulatory momentum around personalized therapies is reinforcing demand for genomic analysis tools.

What's next: - Clinical genomics software vendors are likely to compete more on workflow integration, compliance, data security and cloud scalability. - Wider use of precision medicine and genomic screening programs should keep the market expanding through 2030. - The Asia-Pacific region is positioned to become a major growth engine as adoption broadens outside North America.

The bottom line: - Clinical genomics software is shifting from a specialized research tool to a growing part of mainstream clinical decision-making.